SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

A computational pharmacokinetic-pharmacodynamic framework for simulating and comparing individualized levodopa dosing in Parkinson's disease.

Front Pharmacol · 2026-05-29

DOI: 10.3389/fphar.2026.1817435PMID: 42292794

Open accessresearch-article; Journal ArticleOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

Parkinson's disease is associated with substantial inter-patient variability in motor response to levodopa therapy, making long-term dose selection and scheduling challenging. Computational modeling provides a systematic approach for investigating how pharmacokinetic and pharmacodynamic variability may influence treatment outcomes. This study presents a computational pharmacokinetic-pharmacodynamic framework for simulating and comparing individualized levodopa dosing strategies in Parkinson's disease. The framework integrates multi-compartment drug disposition, effect-site dynamics, and a nonlinear exposure-response relationship, using parameter ranges derived from published clinical and modeling studies. A heterogeneous virtual cohort was generated to represent variability in absorption, clearance, distribution, and pharmacodynamic sensitivity, and simulation-based optimization was applied to evaluate the effects of dose size, dosing interval, and timing across representative patient scenarios. Simulations demonstrated how alternative dosing schedules influence effect-site exposure stability and predicted therapeutic response patterns under inter-patient variability. Sensitivity analysis further identified key parameters contributing most strongly to simulated exposure-response behavior. Rather than providing prescriptive clinical recommendations, the proposed framework serves as an in silico platform for comparing dosing regimens, evaluating scenario-specific strategies, and generating hypotheses for future data-driven validation. These findings highlight the potential of simulation-based PK-PD modeling to support individualized treatment exploration and future model-informed dosing research in Parkinson's disease.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.